Fig. 1. Characterization of the novel human anti-SARS-CoV-2 antibodies.
a Binding curves of polyclonal antibodies in serially diluted serum samples (n = 3 wells per dilution) of COVID-19 patients obtained by ELISA using S1 or RBD as coating antigen. Data represent average of triplicates ±SEM. b Amino acid sequences of the HCDR3 and LCDR3 of the selected antibodies and their respective germ line genes. c Specificity of the selected antibodies determined by ELISA (n = 3 wells per sample) against the indicated SARS-CoV-2 proteins. Data represent average of triplicates ±SEM. d Reactivity profile of antibodies determined by ELISA (n = 3 wells per dilution), using S1 as the coating antigen. Data is presented as binding percent of Bmax for each antibody. The values represent average of triplicates ±SEM. e Binding characteristics of the monoclonal antibodies determined using biolayer interferometry. All antibodies were biotinylated, immobilized to the sensor and interacted with increasing amounts of RBD. Binding kinetics were fitted using the 1:1 binding model.